Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.
Conclusions: These results show a significant effect of sorafenib on muscle mass. However, there was no association between sarcopenia and DMT or early DMT, in contrast to observations in hepatocellular and renal cell carcinoma.
PMID: 31860408 [PubMed - in process]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | CT Scan | Endocrinology | Hepatocellular Carcinoma | Hormones | Iodine | Kidney Cancer | Liver Cancer | PET Scan | Renal Cell Carcinoma | Thyroid | Thyroid Cancer | Toxicology